Eli Lilly, Food and Drug Administration
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized ...
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback